FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W79487760> ?p ?o ?g. }

• W79487760 endingPage "93" @default.
• W79487760 startingPage "289" @default.
• W79487760 abstract "To evaluate the efficacy and safety of Cefaclor in respiratory tract infections amongst Pakistani children.Multicenter, open label and non-comparative study was done to evaluate the response in terms of symptoms (In vivo) and bacterial cultures (In Vitro) to Cefaclor amongst children with respiratory tract infection between the ages 2 months to 12 years. Each patient was asked to visit the doctor on three occasions i.e., Day 0 (Initial evaluation prior to commencement of study), Day 4 (During therapy assessment and confirmation of compliance) and Day 10 (End of therapy assessment and compliance evaluation). Representative swab specimens (Throat swabs, Ear swabs or Sputum) were collected from the infected site on day 0 and day 10 for culture and sensitivity. Patients were also assessed by the evaluators on each visit in terms of clinical symptomatic response and information collected was documented on a prescribed data base form.A total of 160 patients were enrolled in the study, of whom 15 were lost to follow-up between the first and second visit and a further 38 were lost by the 3rd visit. Thus 107 patients completed the study as per protocol. Otitis media and Upper respiratory tract infection were the predominant ailments amongst the cases enrolled. One or more bacteria were isolated in 75 (46%) instances, the maximum number of isolates being from ear swabs of Otitis media patients. Beta haemolytic Streptococcus (group A,C,F,G) seen in 18 cases was the most common pathogen reported followed by Staphylococcus aureus, H. influenzae and Streptococcus pneumoniae in 13,12 and 11 cases respectively. Sensitivity of Cefaclor for bacteria commonly seen in the respiratory tract was greater than 90% in most of the cases. Evaluation of the 42 culture proven cases for patients who completed the study showed that Cefaclor had a 93% efficacy for indicated bacteria and 54% for non-indicated bacteria. In Vivo analysis of Cefaclor (i.e. on the basis of symptomatic response) showed that 96% cases had a symptomatic response by the second visit, which improved to 97% by the third visit. Only 15 non-serious adverse events were observed in 160 patients, none of the cases necessitated discontinuation of drug. Mild gastrointestinal symptom was the most common adverse event reported.Cefaclor was found to be a safe and efficacious drug in the treatment of bacterial respiratory tract infections amongst Pakistani children." @default.
• W79487760 created "2016-06-24" @default.
• W79487760 creator A5002647178 @default.
• W79487760 creator A5006265163 @default.
• W79487760 creator A5011341084 @default.
• W79487760 creator A5013450744 @default.
• W79487760 creator A5020220957 @default.
• W79487760 creator A5021049977 @default.
• W79487760 creator A5051016218 @default.
• W79487760 creator A5053829485 @default.
• W79487760 creator A5057429648 @default.
• W79487760 creator A5058239453 @default.
• W79487760 creator A5070908931 @default.
• W79487760 creator A5076832426 @default.
• W79487760 creator A5081645171 @default.
• W79487760 creator A5083851083 @default.
• W79487760 creator A5091363709 @default.
• W79487760 date "2000-09-01" @default.
• W79487760 modified "2023-09-27" @default.
• W79487760 title "The efficacy and safety of cefaclor in respiratory infections amongst Pakistani children." @default.
• W79487760 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11043017" @default.
• W79487760 hasPublicationYear "2000" @default.
• W79487760 type Work @default.
• W79487760 sameAs 79487760 @default.
• W79487760 citedByCount "3" @default.
• W79487760 crossrefType "journal-article" @default.
• W79487760 hasAuthorship W79487760A5002647178 @default.
• W79487760 hasAuthorship W79487760A5006265163 @default.
• W79487760 hasAuthorship W79487760A5011341084 @default.
• W79487760 hasAuthorship W79487760A5013450744 @default.
• W79487760 hasAuthorship W79487760A5020220957 @default.
• W79487760 hasAuthorship W79487760A5021049977 @default.
• W79487760 hasAuthorship W79487760A5051016218 @default.
• W79487760 hasAuthorship W79487760A5053829485 @default.
• W79487760 hasAuthorship W79487760A5057429648 @default.
• W79487760 hasAuthorship W79487760A5058239453 @default.
• W79487760 hasAuthorship W79487760A5070908931 @default.
• W79487760 hasAuthorship W79487760A5076832426 @default.
• W79487760 hasAuthorship W79487760A5081645171 @default.
• W79487760 hasAuthorship W79487760A5083851083 @default.
• W79487760 hasAuthorship W79487760A5091363709 @default.
• W79487760 hasConcept C126322002 @default.
• W79487760 hasConcept C141071460 @default.
• W79487760 hasConcept C142724271 @default.
• W79487760 hasConcept C187212893 @default.
• W79487760 hasConcept C2776012195 @default.
• W79487760 hasConcept C2776301714 @default.
• W79487760 hasConcept C2776439223 @default.
• W79487760 hasConcept C2776925733 @default.
• W79487760 hasConcept C2778660654 @default.
• W79487760 hasConcept C2779766023 @default.
• W79487760 hasConcept C2780805593 @default.
• W79487760 hasConcept C2781069245 @default.
• W79487760 hasConcept C2781253189 @default.
• W79487760 hasConcept C501593827 @default.
• W79487760 hasConcept C534529494 @default.
• W79487760 hasConcept C64778159 @default.
• W79487760 hasConcept C71924100 @default.
• W79487760 hasConcept C86803240 @default.
• W79487760 hasConcept C89423630 @default.
• W79487760 hasConceptScore W79487760C126322002 @default.
• W79487760 hasConceptScore W79487760C141071460 @default.
• W79487760 hasConceptScore W79487760C142724271 @default.
• W79487760 hasConceptScore W79487760C187212893 @default.
• W79487760 hasConceptScore W79487760C2776012195 @default.
• W79487760 hasConceptScore W79487760C2776301714 @default.
• W79487760 hasConceptScore W79487760C2776439223 @default.
• W79487760 hasConceptScore W79487760C2776925733 @default.
• W79487760 hasConceptScore W79487760C2778660654 @default.
• W79487760 hasConceptScore W79487760C2779766023 @default.
• W79487760 hasConceptScore W79487760C2780805593 @default.
• W79487760 hasConceptScore W79487760C2781069245 @default.
• W79487760 hasConceptScore W79487760C2781253189 @default.
• W79487760 hasConceptScore W79487760C501593827 @default.
• W79487760 hasConceptScore W79487760C534529494 @default.
• W79487760 hasConceptScore W79487760C64778159 @default.
• W79487760 hasConceptScore W79487760C71924100 @default.
• W79487760 hasConceptScore W79487760C86803240 @default.
• W79487760 hasConceptScore W79487760C89423630 @default.
• W79487760 hasIssue "9" @default.
• W79487760 hasLocation W794877601 @default.
• W79487760 hasOpenAccess W79487760 @default.
• W79487760 hasPrimaryLocation W794877601 @default.
• W79487760 hasRelatedWork W1513626512 @default.
• W79487760 hasRelatedWork W155244011 @default.
• W79487760 hasRelatedWork W158227432 @default.
• W79487760 hasRelatedWork W1982799254 @default.
• W79487760 hasRelatedWork W2005379728 @default.
• W79487760 hasRelatedWork W2150688627 @default.
• W79487760 hasRelatedWork W2171294198 @default.
• W79487760 hasRelatedWork W2415455695 @default.
• W79487760 hasRelatedWork W3213887131 @default.
• W79487760 hasRelatedWork W79487760 @default.
• W79487760 hasVolume "50" @default.
• W79487760 isParatext "false" @default.
• W79487760 isRetracted "false" @default.
• W79487760 magId "79487760" @default.
• W79487760 workType "article" @default.